Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,699.00
Bid: 1,698.50
Ask: 1,699.50
Change: -6.00 (-0.35%)
Spread: 1.00 (0.059%)
Open: 1,705.00
High: 1,711.00
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Mining rebound lifts markets higher

Fri, 19th Apr 2013 11:57

The FTSE 100 rebound on Friday morning after a five-day losing streak as strong gains in the mining sector lifted London's benchmark higher."Clients who went bargain hunting in the mining space after the aggressive sell-off earlier in the week have been rewarded this morning, as the sector bounces back strongly early on," said Matt Basi, the Head of UK Sales Trading at CMC Markets.Ahead of today's session, the FTSE 100 had lost 2.7% of its value after five consecutive falls as disappointing US earnings and concerns over global growth weighed on sentiment.First-quarter economic gross domestic product figures from China, a plummeting gold price and downwards revisions to global growth forecasts by the International Monetary Fund caused some volatile swings in the mining sector earlier this week. Before today, FTSE 350 mining stocks had fallen by an average 9.14% since last Friday.FTSE 100: Miners provide a liftMining stocks were performing well after a volatile week for the sector. ENRC, Vedanta, EVRAZ and Randgold were all making decent gains by lunchtime.Anglo American was also a high riser after announcing that production at its larger operations of iron ore and copper increased in the first quarter, when compared with last year, despite the company scaling back spending.Meanwhile, telecoms firm Vodafone was also in demand as rumours continue to circulate surrounding a buy-out of its 45% stake in its US wireless joint venture with Verizon. According to reports this morning, a deal could happen this year as fears about tax obstacles ease.GlaxoSmithKline was trading lower ahead of its first-quarter update next week. There were reports this morning that the company is being investigated over claims it paid off firms to delay the launch of cheap versions of its anti-depression drug.FTSE 250: Spectris plummets after weak first quarterSpectris, the electrical engineering firm, plummeted after reporting an 8.0% fall in first-quarter sales, reflecting a deferral of orders and shipment delaysHigh Street bookie William Hill surged early on despite reporting that growth had moderated during the first quarter. The firm did say however that the Grand National after the quarter-end was a "major success", beating its record win achieved on the race in 2009.Online information and events group Euromoney fell after announced that it has acquired a 75% stake in the Australian provider of investment forums, Centre for Investor Education.
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.